Compare Endeavour Silver Corp (EXK) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Endeavour Silver Corp trades at $7.95 (market cap $2.44B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Endeavour Silver Corp is far larger — about 2.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 26 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EXK | MRVI | |
|---|---|---|
Market Cap | $2.44B | $972.90M |
Volume | 5,983,279 | 4,325,710 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $9.00 |
52-Week Low | $7.07 | $2.83 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $2.44B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.24, down 3.51% on the day, amid a bearish technical signal with moving averages indicating selling pressure. The company reported a net loss of $119.1 million in 2025 but improved to a net profit of $66 million in 2026, driven by revenue growth from $468 million to $737 million. Recent news highlights operational progress at the Terronera mine and a temporary mechanical issue at Guanacevi, while analyst consensus remains strongly positive with 11 buy ratings.
The outlook for EXK hinges on successful execution of mine expansions and favorable silver prices, offering growth potential, but risks include operational disruptions, commodity price volatility, and high valuation multiples. Investors should weigh the strong analyst support against near-term profitability challenges and market sentiment.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
